Research interests include Cancer Immunotherapy and Biomarkers, Immunotherapy and Immune Responses, Autophagy in Disease and Therapy, and Cancer, Hypoxia, and Metabolism.
NCOA3 impairs the efficacy of anti-PD-L1 therapy via HSP90α/EZH2/CXCL9 axis in colon cancer
International Immunopharmacology2025cited by 23position: middledoi
Low-dose radiotherapy combined with dual PD-L1 and VEGFA blockade elicits antitumor response in hepatocellular carcinoma mediated by activated intratumoral CD8+ exhausted-like T cells
Nature Communications2023cited by 72position: middledoi